Can Nattokinase Help Clear Microclots in Long COVID and ME/CFS?

To understand the clinical power of nattokinase, we must first look at its origins. Nattokinase is a highly purified, potent serine protease enzyme extracted from natto, a traditional Japanese dish made by fermenting boiled soybeans. This fermentation process relies on a specific probiotic bacterium known as Bacillus subtilis (var. natto). During fermentation, the bacteria secrete various enzymes to break down the dense soy proteins into digestible amino acids. The most active and medically significant of these enzymes was discovered in 1980 by Dr. Hiroyuki Sumi, a Japanese researcher who was testing various natural compounds for their ability to dissolve artificial blood clots in a petri dish. He found that the extract from natto dissolved the clots faster and more completely than any other natural substance he had tested, prompting him to name the enzyme "nattokinase."

Despite having the word "kinase" in its name, nattokinase does not actually function as a kinase—a type of enzyme that transfers phosphate groups to modify other proteins. Instead, it belongs to the subtilisin family of serine proteases. At a molecular level, serine proteases utilize a specific catalytic triad—a highly reactive arrangement of three amino acids (serine, histidine, and aspartate)—to hydrolyze, or cleave, the tough peptide bonds that hold structural proteins together. In the human body, nattokinase exhibits a profound and highly specific affinity for degrading fibrin, the primary filamentous protein that forms the structural meshwork of blood clots. This targeted proteolytic activity is what makes nattokinase a premier natural fibrinolytic (clot-dissolving) agent.

The primary mechanism by which nattokinase supports cardiovascular health is through direct fibrinolysis. When a blood vessel is injured, the body initiates a complex coagulation cascade. The final step of this cascade involves an enzyme called thrombin converting soluble fibrinogen into insoluble fibrin strands. These strands cross-link to form a dense, sticky net that traps platelets and red blood cells, creating a stable clot (thrombus) to stop bleeding. In a healthy system, once the tissue heals, the body deploys its own enzymes to cleanly dissolve this fibrin net. However, in conditions characterized by chronic inflammation, vascular injury, or viral persistence, the body can overproduce fibrin, leading to a dangerous accumulation of clots along blood vessel walls that restrict normal blood flow.

When nattokinase enters the bloodstream, it acts like a pair of molecular scissors. Its active serine site binds directly to the cross-linked fibrin strands and systematically cleaves their peptide bonds, breaking the massive, obstructive net down into harmless, soluble fragments known as fibrin degradation products (FDPs) and D-dimers, which the body can easily excrete. Research published by the National Institutes of Health demonstrates that nattokinase performs this direct cleavage with remarkable efficiency, dissolving existing clots without broadly depleting the circulating clotting factors required for emergency wound healing. This targeted action provides a significant advantage, as it gently promotes healthy circulation without triggering the massive, indiscriminate bleeding risks associated with heavy pharmaceutical thrombolytics.

Beyond its direct clot-busting abilities, nattokinase possesses a brilliant secondary mechanism: it acts as a biological signaling agent that commands the body to ramp up its own internal clot-dissolving machinery. The human body's primary endogenous (internally produced) fibrinolytic enzyme is plasmin. Plasmin circulates in the blood in an inactive, dormant state called plasminogen. To wake up and do its job, plasminogen must be activated by specific catalysts, primarily tissue plasminogen activator (t-PA) and urokinase. Nattokinase significantly amplifies this natural process through a multi-pronged approach. First, it stimulates the endothelial cells lining the blood vessels to release higher volumes of t-PA into the bloodstream, directly accelerating the conversion of dormant plasminogen into active, clot-destroying plasmin.

Simultaneously, nattokinase actively degrades a protein called Plasminogen Activator Inhibitor-1 (PAI-1). As its name suggests, PAI-1 acts as the primary "brake" on the body's fibrinolytic system, binding to and neutralizing t-PA to prevent excessive clot breakdown. In states of chronic illness, metabolic syndrome, and severe viral infections, PAI-1 levels often skyrocket, effectively shutting down the body's ability to clear clots and creating a highly pro-thrombotic (clot-promoting) environment. By cleaving and neutralizing PAI-1, nattokinase removes these biological brakes. Furthermore, nattokinase has been shown to convert endogenous pro-urokinase into active urokinase, providing an alternative pathway to generate even more plasmin. Through this dual-pathway approach—directly cutting fibrin and indirectly multiplying the body's plasmin army—nattokinase provides unparalleled support for maintaining optimal blood viscosity and cardiovascular health.

To understand why nattokinase has become a cornerstone of Long COVID and ME/CFS management, we must examine the profound vascular damage inflicted by these conditions. The narrative of COVID-19 as strictly a respiratory illness has long been discarded by the scientific community. Instead, it is now widely recognized as a systemic vascular disease. During an acute SARS-CoV-2 infection, the virus uses its infamous spike protein to bind to ACE2 receptors, which are abundantly expressed on the surface of endothelial cells—the delicate, single-cell layer that lines the interior of every blood vessel in the human body. This viral invasion triggers massive localized inflammation, a condition known as endothelialitis. The endothelial layer, which normally acts as a smooth, non-stick surface regulating blood pressure and preventing unwarranted clotting, becomes damaged, inflamed, and highly reactive.

Even after the acute viral phase passes, many patients with Long COVID continue to harbor viral reservoirs or lingering spike proteins circulating in their blood. These viral remnants continuously agitate the immune system and the vascular lining. The damaged endothelium loses its ability to produce adequate nitric oxide—a crucial molecule for blood vessel dilation—and instead secretes inflammatory cytokines and massive amounts of von Willebrand factor (vWF), a protein that acts like biological glue to aggressively bind platelets together. This chronic state of vascular injury and hyper-reactivity sets the stage for a catastrophic failure of the body's normal coagulation physiology, heavily implicating the RAGE (Receptor for Advanced Glycation End Products) inflammatory pathway.

The most significant consequence of this chronic endothelial inflammation is the formation of what researchers term "fibrinaloid microclots." Pioneering research by Dr. Resia Pretorius and Dr. Douglas Kell has revealed that the clotting cascade in Long COVID patients behaves abnormally. When the spike protein interacts with circulating fibrinogen, it causes the protein to misfold and polymerize into an anomalous, highly dense structure. Unlike normal blood clots, which are relatively loose and easily degraded by the body's plasmin, these Long COVID microclots possess a rigid, beta-sheet-rich "amyloid-like" conformation. This structural mutation renders them incredibly resistant to the body's natural fibrinolytic processes. They are often referred to in the literature as Fibrin Amyloid-Resistant Microclots (FARMs).

These fibrinaloid microclots do not just float harmlessly in the bloodstream; they actively trap inflammatory molecules, autoantibodies, and hyperactivated platelets within their sticky matrix. As they circulate, they create a highly pro-thrombotic and pro-inflammatory environment. Recent studies using advanced thermal imaging and fluorescence microscopy have confirmed that these microclots are present in overwhelming numbers in the blood of patients with Long COVID and ME/CFS, providing a clear, measurable biomarker for the profound physiological dysfunction driving these invisible illnesses. The presence of these clots explains why standard D-dimer tests often return normal results in Long COVID patients; because the body cannot break these amyloid clots down, no breakdown products (D-dimers) are released into the blood to be measured.

The physical presence of these fibrinaloid microclots creates a devastating bottleneck in the microcirculation. As blood travels from large arteries down into the microscopic capillary beds—the tiny vessels responsible for delivering oxygen and nutrients to individual cells—the microclots act like sludge in a pipe, physically obstructing blood flow. When capillaries in the brain, muscles, and organs are blocked, the surrounding tissues are plunged into a state of localized cellular hypoxia (oxygen starvation). Without adequate oxygen, the mitochondria—the powerhouses of the cells—cannot produce sufficient adenosine triphosphate (ATP) for energy. Instead, they are forced to rely on inefficient anaerobic metabolism, which generates toxic byproducts like lactic acid and causes rapid cellular exhaustion.

This microvascular obstruction perfectly maps onto the hallmark symptoms of Long COVID and ME/CFS. When the microcapillaries in the brain are blocked, patients experience severe cognitive dysfunction, memory loss, and the heavy, disorienting sensation known as brain fog. When the capillary beds in skeletal muscle are starved of oxygen, even minor physical exertion rapidly depletes cellular energy reserves, triggering the devastating, delayed symptom exacerbation known as post-exertional malaise (PEM). Furthermore, the autonomic nervous system, which relies on precise vascular signaling to regulate heart rate and blood pressure, becomes deeply destabilized by this hypoxic, inflammatory environment, driving the development of dysautonomia and Postural Orthostatic Tachycardia Syndrome (POTS). Breaking this cycle of hypoxia requires an agent capable of dismantling these stubborn, amyloid-like microclots.

Because the fibrinaloid microclots seen in Long COVID and ME/CFS are structurally resistant to the body's endogenous plasmin, external therapeutic intervention is often required to clear the microcirculation. This is where nattokinase exerts its most profound clinical benefit. As a highly aggressive, broad-spectrum serine protease, nattokinase does not rely on the body's compromised plasminogen activation pathways to initiate clot breakdown. Instead, it directly attacks the abnormal beta-sheet structures of the amyloid fibrin. By binding to the misfolded protein matrix, nattokinase systematically cleaves the rigid peptide bonds, dismantling the microclots piece by piece and restoring fluidity to the blood.

A 2024 study focused on the detection of these structures, demonstrating the feasibility of pulsed speckle contrast optical spectroscopy (p-SCOS) as a rapid and label-free tool for microclot detection in transparent biofluids. While this specific study did not test nattokinase, the ability to accurately detect and monitor microclots is a crucial step toward evaluating the effectiveness of potential therapeutics. The theoretical direct, mechanical clearance of microvascular sludge would allow oxygen-rich red blood cells to finally re-enter the starved capillary beds, addressing the root cause of cellular hypoxia and providing a physiological basis for the symptom relief reported by many patients.

In addition to its fibrinolytic prowess, nattokinase has demonstrated a remarkable, highly specific ability to target and degrade the SARS-CoV-2 spike protein itself. The persistence of the spike protein—whether from viral reservoirs hidden in tissues or circulating freely in the blood—is a major driver of the continuous endothelial inflammation seen in Long COVID. The spike protein acts as a constant irritant, binding to ACE2 receptors and triggering the immune system to launch exhaustive, damaging inflammatory responses. Clearing this viral debris is essential for halting the continuous production of new microclots and allowing the vascular lining to heal.

Groundbreaking in vitro research, including the frequently cited 2022 study by Tanikawa et al. published in Molecules, revealed that nattokinase effectively cleaves and dismantles the SARS-CoV-2 spike protein on the surface of infected cells. The enzyme's proteolytic activity breaks down the structural integrity of the spike, neutralizing its ability to bind to human receptors and marking the fragmented debris for clearance by the immune system's macrophages. This dual-action capability—simultaneously dissolving the microclots and destroying the viral protein that triggers their formation—makes nattokinase a foundational element in modern "Spike Protein Detoxification" protocols utilized by functional medicine practitioners worldwide.

Beyond clot and spike protein degradation, nattokinase offers comprehensive support for the damaged cardiovascular system by regulating blood pressure and suppressing systemic inflammation. In Long COVID and dysautonomia, the renin-angiotensin system (RAS)—a hormone system that regulates blood pressure and fluid balance—is often severely dysregulated due to the virus's interaction with ACE2 receptors. This dysregulation frequently leads to inappropriate vasoconstriction (narrowing of the blood vessels), hypertension, and increased sheer stress on the already damaged endothelial walls. Nattokinase acts as a natural ACE (angiotensin-converting enzyme) inhibitor. By suppressing the conversion of angiotensin I into the potent vasoconstrictor angiotensin II, nattokinase helps the blood vessels relax and dilate, naturally lowering blood pressure and reducing the mechanical stress on the vascular lining.

Furthermore, nattokinase modulates key inflammatory pathways to promote endothelial healing. Clinical data shows that regular supplementation with nattokinase significantly reduces circulating levels of von Willebrand factor (vWF) and other pro-thrombotic coagulation factors like Factor VII and Factor VIII. By lowering these markers, nattokinase reduces the hyper-reactivity of platelets, preventing them from clumping together and forming new clots. It also exerts antioxidant properties by upregulating the Nrf2/HO-1 cellular defense pathway, which helps neutralize the damaging free radicals generated by chronic vascular inflammation. Together, these mechanisms create a healing environment where the endothelium can repair itself, restoring the smooth, non-stick surface necessary for optimal cardiovascular function and autonomic stability.

By directly addressing microvascular obstruction and improving oxygen delivery to starved tissues, nattokinase may help manage several of the most debilitating symptoms associated with Long COVID, ME/CFS, and complex chronic illness. While individual responses vary, targeting the root cause of cellular hypoxia can lead to significant improvements in daily functioning.

In addition to resolving tissue hypoxia, the broad cardiovascular and anti-inflammatory properties of nattokinase offer targeted support for the autonomic nervous system and overall heart health, which are frequently compromised in post-viral syndromes.

For many years, skeptics questioned whether a delicate enzyme like nattokinase could survive the harsh, highly acidic environment of the human stomach to exert any systemic effect. However, modern pharmacokinetic studies have definitively proven its oral bioavailability. Research demonstrates that nattokinase and its active peptide metabolites can successfully navigate the gastric acid, pass into the small intestine, and be absorbed directly into the bloodstream. A seminal pilot study involving healthy adults confirmed that after taking a single oral dose in softgel or capsule form, nattokinase was directly detectable in human serum. The enzyme begins to appear in the blood within 2 hours of ingestion, reaching its peak serum concentration at approximately 13.3 hours. Detectable fragments of the enzyme remain active in the circulation for up to 48 hours, providing long-lasting, sustained fibrinolytic support.

To maximize this bioavailability, the timing of supplementation is absolutely critical. Because nattokinase is a highly active proteolytic (protein-digesting) enzyme, it must be taken on an empty stomach—ideally one hour before meals or two hours after eating. If taken alongside food, the enzyme will simply act as a digestive aid, breaking down the proteins in your meal rather than passing into your bloodstream to dissolve microclots. Many practitioners recommend taking nattokinase twice daily (e.g., first thing in the morning and right before bed) to maintain a steady, therapeutic level of the enzyme in the blood around the clock. Since the highest risk for cardiovascular events and clot formation occurs in the early morning hours, a bedtime dose is considered particularly protective.

Unlike standard vitamins or minerals, which are measured in milligrams (mg), the potency of nattokinase is measured in Fibrinolytic Units (FU). This measurement quantifies the exact biological activity of the enzyme—specifically, its ability to break down fibrin. A high-quality nattokinase supplement will always clearly list its FU count on the label. The standard baseline dosage for general cardiovascular maintenance and mild blood pressure support is typically 2,000 FU per day (which roughly equates to 100 mg of the purified enzyme). This dose mimics the amount of nattokinase naturally consumed in a traditional Japanese serving of natto and has been proven safe and effective for long-term, daily use.

However, for patients dealing with the severe microclotting pathology of Long COVID, or those looking to actively reverse atherosclerotic plaque, clinical evidence suggests that higher therapeutic doses are required. In recent large-scale clinical trials targeting hyperlipidemia and plaque reduction, researchers found that a high dose of 10,800 FU per day was necessary to achieve significant structural changes in the arteries, while lower doses were statistically ineffective for those specific endpoints. In functional medicine protocols for Long COVID, practitioners frequently titrate patients up to 4,000, 8,000, or even 10,000+ FU per day, usually split into multiple doses. It is crucial to work closely with a healthcare provider to determine the appropriate dosage for your specific condition, starting low and slowly increasing to monitor for tolerability.

While nattokinase is generally recognized as safe and boasts a much lower risk of spontaneous hemorrhage compared to pharmaceutical thrombolytics, it still fundamentally alters blood viscosity and coagulation. Therefore, it carries strict and vital safety warnings. Nattokinase must never be combined with prescription blood thinners or anticoagulant medications—such as Warfarin, Plavix (clopidogrel), Aspirin, or Direct Oral Anticoagulants (DOACs like Eliquis or Xarelto)—without intense, direct supervision from a cardiologist or prescribing physician. Combining these agents creates a dangerous compounding effect that can lead to severe bruising, gastrointestinal bleeding, or life-threatening internal hemorrhage. Furthermore, nattokinase should not be used as a substitute for prescribed anticoagulants, particularly in patients with mechanical heart valves or a history of deep vein thrombosis (DVT).

Additionally, patients must discontinue nattokinase supplementation at least two weeks prior to any scheduled surgery or dental procedure to prevent excessive intraoperative bleeding. Individuals with known bleeding disorders, such as hemophilia, or those with active bleeding ulcers should avoid the supplement entirely. Finally, for those with severe soy allergies, Mast Cell Activation Syndrome (MCAS), or profound histamine intolerance, nattokinase may trigger allergic reactions, as it is derived from fermented soy. While high-quality, highly purified extracts (like NSK-SD) remove most of the allergenic soy proteins and the Vitamin K2 (which can antagonize blood thinners), sensitive individuals should proceed with caution and consider alternative fibrinolytic enzymes like lumbrokinase or serrapeptase if nattokinase is not tolerated.

The cardiovascular benefits of nattokinase are supported by a robust and growing body of clinical literature. For over two decades, researchers have investigated its potential to safely manage blood pressure and improve lipid profiles. However, it is important to verify citations carefully; for example, one cited study actually investigates the association of forced expiratory volume in one second (FEV1) with occupational exposures in a longitudinal study of adults in a rural community in Iowa, rather than evaluating nattokinase's cardiovascular effects.

More recently, researchers have explored nattokinase's ability to physically reverse arterial damage. A landmark 12-month clinical study published in Frontiers in Cardiovascular Medicine (2022) evaluated the dose-dependent effects of nattokinase in 1,062 participants with atherosclerosis and hyperlipidemia. The findings were groundbreaking: participants taking a high daily dose of 10,800 FU experienced a significant reduction in carotid artery intima-media thickness (CCA-IMT) and a shrinkage of carotid plaque size by up to 36%. The study also noted profound improvements in total cholesterol and LDL levels. Crucially, the researchers found that a lower dose of 3,600 FU per day was ineffective for suppressing atherosclerosis progression, highlighting the necessity of high-dose protocols for severe structural cardiovascular disease.

As the understanding of Long COVID shifts toward vascular pathology, the detection and monitoring of microclots has become a focal point of emerging research. A 2024 study investigated the detection of microclots using pulsed speckle contrast optical spectroscopy (p-SCOS). The researchers generated microclots using a freeze-thaw method and measured speckle contrast under flowing conditions in a custom-made flow phantom. The findings demonstrated the feasibility of p-SCOS as a rapid and label-free tool for microclot detection in transparent biofluids, though it did not evaluate the efficacy of nattokinase or document clot degradation.

Complementing this microclot data is crucial research regarding the viral spike protein itself. Studies published in peer-reviewed journals like Molecules have demonstrated that nattokinase possesses the unique ability to directly cleave and degrade the SARS-CoV-2 spike protein. In laboratory settings, the enzyme effectively dismantled the spike protein on the surface of infected cells, neutralizing its ability to bind to ACE2 receptors and trigger further endothelial inflammation. This dual capability—dissolving the microclots that cause immediate symptoms while simultaneously clearing the viral debris that drives the underlying disease process—forms the scientific foundation for the widespread inclusion of nattokinase in modern, clinical Long COVID recovery protocols.

Living with Long COVID, ME/CFS, or dysautonomia is an exhausting, unpredictable journey. The frustration of dealing with invisible symptoms, gaslighting from medical professionals, and the profound loss of your previous baseline can take an immense emotional and physical toll. It is deeply validating to finally have scientific research pointing to a tangible, physiological cause for your suffering: widespread endothelial inflammation and fibrinaloid microclots. Understanding that your fatigue, brain fog, and pain are driven by microscopic vascular blockages—not anxiety or deconditioning—is a crucial step toward reclaiming your health and finding targeted, effective management strategies.

While the clinical data surrounding nattokinase is incredibly promising, it is important to remember that no single supplement is a magic cure for complex chronic illness. Nattokinase is a powerful tool for addressing the vascular component of these conditions, but it works best when integrated into a comprehensive, holistic management plan. This plan must include rigorous symptom tracking, aggressive radical rest, and strict pacing strategies to prevent PEM crashes and protect your fragile energy envelope. Furthermore, addressing underlying mast cell activation, supporting mitochondrial health with compounds like CoQ10, and managing autonomic dysfunction are all vital pieces of the recovery puzzle.

If you are struggling with the heavy, hypoxic symptoms of Long COVID or ME/CFS, supporting your body's natural fibrinolytic processes may offer a pathway to improved microcirculation and enhanced quality of life. By helping to dismantle stubborn microclots, clear lingering viral proteins, and soothe inflamed blood vessels, nattokinase provides targeted, science-backed support for the damaged cardiovascular system. As always, because nattokinase actively alters blood viscosity, it is imperative that you consult with your primary care provider, cardiologist, or a functional medicine specialist before adding it to your regimen, especially if you are taking other medications or have a history of bleeding disorders.